INTRODUCTION
There have been extensive research efforts to demonstrate comprehensive involvement of gut microbiota in diverse pathophysiological processes through interact with host cells. The host-gut microbiota metabolic interactions start at our birth and continue throughout our life, and maintain host health through generating numerous endogenous co-metabolites of biological importance (Nicholson et al., 2012) . Thus manipulating microbial balance using probiotics, nutrients, and antibiotics represent promising therapies in patients with disorders caused by microbial imbalances (Foxx-Orenstein and Chey, 2012) . On the other hand, the tremendous metabolic capability of gut microbiota is also of great importance in biotransforming structurally diverse xenobiotics into more permeable metabolites.
Therefore, in some alternative medical systems where the medicines are usually applied orally, the pre-systemic interaction with gut microbiota may define both the disposition profile and the pharmacological activity of the medicine. However, elucidation of the presystemic interactions has generally not been included into the work portfolio of the medicine until recently.
Glycosides are major components composed by aglycone and. In general, the glycosides are fairly soluble in water and possess poor membrane permeability.
Among many glycosides found in nature, flavonoid glycosides belong to an important chemical type which ubiquitously distribute in the plant kingdom, including fruits, vegetables, soy products and some medicinal herbs. Some health related benefits associated with this group of compounds include strengthening of the immune system, D M D # 6 5 0 9 4 5 protecting against cancer, and reducing capillary fragility (Lu MF et al., 2013) . Since many flavonoid glycosides exhibit low oral bioavailability due to microbial hydrolysis and conjugation that occurs in the intestine and the liver, this type of compounds are generally considered as natural pro-drugs (Arroo et al, 2008 (Arroo et al, , 2009 , and their health benefits are attributed to the metabolites capable of reaching the circulation (Dorjgochoo et al., 2012; Vissiennon et al., 2012; Romano et al., 2013) . However, biological/pharmacological evaluation of the resultant conjugates was rather few (Terao, 1999; Koga and Meydani, 2001) due to limited access to the pure compounds.
The actions of the parent compounds prior to intestinal absorption are generally ignored.
Astragali Radix is a medicinal herb notable for its immunogenic effect (Zhao et al., 2008) . In addition to applications for immunity enhancement, the herb is widely utilized for treatment of cardiovascular diseases such as heart failure, angina pectoris, myocardial infarction and stroke in Asian countries (Zhao et al., 2008) . Our recent study using a MRM-based approach revealed over 400 flavonoids in the herb, among which around 130 are calycosin (7,3'-dihydroxy-4'-methoxyisoflavone) and its glycosides . As the most abundant and characteristic flavonoid compound in Astragali Radix (Lv et al., 2011), calycosin-7-O-β-D-glucoside (C7G) has been documented in China Pharmacopoeia (Chinese Pharmacopoeia Commission, 2010) as one of the markers for quality control of the herb. Recently, this herb has been acclimated to European countries for phytotherapeutic purposes (Matkowski et al., 2003) .
In concert with the clinical applications of Astragali Radix, C7G exhibited anti-inflammatory effect in rabbit osteoarthritis model (Choi et al., 2007) and anti-oxidative and neuroprotective effects in vitro (Yu et al., 2005) . The aglycone calycosin demonstrated anti-diabetic (Shen et al., 2006) , anti-oxidative and neuroprotective (Yu et al., 2005) , and cardiovascular protective effects (Fan et al., 2003) in vitro. Our recent study (Tang et al., 2010; Li et al., 2011) found that calycosin acted as a selective estrogen receptor modulator to promote angiogenesis in zebrafish embryos and human umbilical vein endothelial cell (HUVEC) cultures. A pharmaceutical composition consisting of calycosin and C7G has been patented for prevention and treatment of estrogen receptor-mediated diseases (US2009/0258942 A2) and diabetic nephropathy (WO2010/081264 A1).
However, as is widely known for flavonoids, both C7G and calycosin are likely pro-drugs and calycosin conjugates could be the pharmacologically active form.
Calycosin phase II conjugates appeared to be the primary circulating forms present following an oral administration of C7G to rats (Chen et al., 2011; Zhang et al., 2012) or administration of Astragali Radix extract to a healthy volunteer (Xu et al., 2006) .
These findings indicate the occurrence of deglycosylation of C7G and further conjugation of calycosin. Our recent study revealed major glucuronidation and moderate sulfation of calycosin and identified 3′-O-glucuronide as the major conjugate formed in human liver microsomes (Ruan and Yan, 2014 system after oral administration of C7G, and more importantly, whether the circulating metabolites of C7G in the blood possess relevant pharmacological properties, remain unclear.
Therefore, this work was designed to study the presystemic interplay between C7G and gut microbiota and disposition of C7G after oral administration. In addition, this work evaluated the angiogenic activities of the major circulating forms of C7G using zebrafish larvae and HUVEC.
Materials and Methods

Materials
Calycosin and C7G standards (purity > 98%) were purchased from Foreverbiotech Company (Shanghai, China). Calycosin-3′-O-glucuronide (G2) (purity > 98)
was prepared from a large-scale reaction of calycosin with rat liver microsomes and identified using NMR analysis in our laboratory (Ruan and Yan, 2014 
Microbial metabolism of calycosin-7-O-β-D-glucoside and calycosin
Rat gut microbiota samples were prepared according to our previous report (Ruan et al., 2010) .
Briefly, a total of 10 grams of fresh fecal samples were collected from 5 rats and pooled at equal amounts, then mixed well with 30 mL of autoclaved BHI medium.
The resultant fecal suspension was centrifuged and the supernatant was decanted and centrifuged at 5,000 g for 30 min. The precipitate was re-suspended with 10 mL BHI medium to provide gut bacterial suspension (0.1 g/mL).
Biotransformation of C7G or calycosin by rat intestinal bacteria was determined in a 0.5 mL incubation system containing 25 Collection. Cells at passage 30-40 were cultured in DMEM according to a protocol reported previously (Ruan et al., 2010) . Briefly, after 21 days of culture, the prepared Caco-2 monolayers were rinsed twice with HBSS and pre-incubated in HBSS at 37 o C for 30 min. In the absorptive transport study, 0.5 mL of HBSS solutions containing C7G or calycosin (final concentration 12.5, 25, 50, or 100 μ M) were loaded at the apical (A) side (donor chamber), and 1.5 mL of blank HBSS was placed at basolateral (B) side (receiver chamber). In the secretory transport study, 1.5 mL of HBSS containing the test compound was added at the B side (donor chamber) and 0.5 mL of blank HBSS was placed at the A side (receiver chamber). Aliquots (100 μL) were taken from receiver chambers at different time intervals (0, 15, 30, 45, 60 min) for sample analysis. After each sampling, 0.1 mL HBSS was added to the receiver chamber to maintain a constant volume. All the experiments were performed in triplicate.
The apparent permeability coefficients (P app ) of C7G and calycosin from apical side to basolateral side (P app A to B ) or from basolateral side to apical side (P app B to A )
obtained from the bidirectional transport study using the Caco-2 cell model were calculated using the following equation (Schrickx and Fink-Gremmels, 2007) :
where dC/dt is the rate of the tested compound appearing in the receiver chamber, V is the volume of the solution in the receiver chamber, C 0 is the initial concentration of the tested compound added in the donor chamber, and A is the cell monolayer surface area.
Hepatic metabolism of calycosin-7-O-β-D-glucoside and calycosin Phase
II (sulfation and glucuronidation) reactions of C7G and calycosin in rat liver subcellular fractions were carried out according to the method recently reported by our group (Ruan and Yan, 2014) . Glucuronidation reaction was carried out in rat liver microsomes at 0.1 mg protein/mL and incubated for 10 min. Sulfation was examined with pooled rat liver S9 at 1 mg/mL and the reaction was allowed to proceed for 60 
Pharmacokinetic study of calycosin-7-O-β-D-glucoside in the rat
The in vivo pharmacokinetic study was performed according to a protocol reported previously with minor modifications. In brief, a cannula was implanted into the jugular vein for blood sampling prior to the experiment. After cannulation, rats were allowed to recover and fasted overnight with free access to water. C7G was dissolved at 10 mg/mL in a solution consisting of PEG 400 and water followed by adding three volumes of methanol to precipitate proteins. After centrifugation (20,000 g, 10 min), the supernatant was filtered and subjected to HPLC-MS/MS analysis.
Calibration curves of C7G, calycosin and G2 in rat plasma
Stock solutions of C7G, calycosin and G2 were prepared in methanol and diluted to 8 different concentrations. An aliquot of each solution was spiked with pooled rat plasma to achieve final concentrations of C7G, calycosin and G2 within 4.88-5000, 4-88-5000, 2.44-40000 nM, respectively. The resultant mixture was processed as described above and analytes were determined by LC-MS/MS. The calibration curves were constructed by plotting peak area ratio of the analyte to the internal standard as a function of the concentration of the analyte. Intra-(3 replicates within a day) and inter-day (3 replicates per day over 3 days) variations were measured at two concentration levels to determine the precision and accuracy. The limit of detection Tables 1 and 2) .
HPLC-DAD analysis
Samples from the transport study and in vitro metabolic studies were analyzed on an Agilent 1200 series HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with a vacuum degasser, a binary pump, an autosampler and DAD. Samples were separated on an Agilent ODS reversed-phase 40, ion source gas 2 (GS2) 40, collision gas (CAD) High, scan range m/z 100-600.
Plasma samples were analyzed in MRM mode by monitoring the ion pair 480.9/282.9, 282.9/267.9, 459.0/282.8 and 362.8/282.8 for C7G, calycosin, calycosin mono-glucuronides and calycosin mono-sulfates, respectively.
Bioactivity Assays
Effects of C7G on growth of gut microbiota from normal rats and rats with experimental colitis
Animal treatment and fecal bacteria preparation Twelve rats (200~250g) were randomly divided into two groups (6 animals each). One group received drinking water for 7 days (normal group), while the other was orally administerd 5% DSS via the drinking water to induce experimental colitis (UC group) as described in our recent report (Huang et al., 2015) . Fecal samples were freshly collected from each group on the last day of DSS treatment, and pooled each within group to prepare bacterial suspensions (0.1 g bacteria/mL medium). 
Incubation of C7G with rat gut bacteria
Angiogenesis assay on in vivo zebrafish model
Zebrafish embryos were prepared as described in our previous work (Tang et al., 2010) . Briefly, Zebrafish time zero to infinity (AUC 0-∞ ) was calculated using log-trapezoidal rule. The elimination half-life (t 1/2 ) was estimated from the terminal slope (-ke/2.303) of the plasma concentration-time curve.
All data were presented as means ± SD unless otherwise mentioned. The differences between groups were compared using Student's t-test or one-way ANOVA followed by Tukey's multiple comparison test. P< 0.05 was deemed significant.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
In vivo oral pharmacokinetics of C7G in rats When C7G was orally administrated to the rats, the parent C7G was not detected in the plasma throughout the experimental period 24 h. Its aglycone calycsoin can only be detected in minor amounts in plasma samples collected at 6 min and 10 min from only two rats (data not was unambiguously identified as calycosin. C7G was time dependently decreased by the gut microbiota and was depleted within 2 h ( Figure 2C ). Meanwhile, B1 showed a quick increase, reached a plateau at about 2 h and remained constant afterwards.
When incubated alone, calycosin remained intact in rat gut microbiota within 2 h.
These results indicated that calycosin is quite stable in rat gut bacteria. 
Transport of C7G and calycosin across Caco-2 cell monolayer
Incubation with C7G stimulated the growth of Lactobacillus and Bifidobacterium in gut bacteria from normal and colitic rats
As shown in Figure 6 , when gut bacteria from normal rats were incubated in vitro, the relative contents of
Lactobacillus and Enterobacteriaceae were increased with maximum levels observed at 6h and 2h, respectively, while that of Bifidobacterium declined slowly with time.
The presence of C7G resulted in a marked increase in the relative content of
Lactobacillus and slightly enhanced the relative contents of Bifidobacterium and Enterobacteriaceae in gut microbiota from normal rats at early stage of incubation (2 h). In gut microbiota from colitic rats, C7G treatment enhanced the relative content of Lactobacillus in a similar trend. More interestingly, the relative content of Bifidobacterium showed an increase at 2 h of incubation and the presence of C7G
further enhanced the relative content by 2.7-fold. The growth of Enterobacteriaceae from rats with experimental colitis followed a biphasic increase and the relative content was not altered by C7G.
This article has not been copyedited and formatted. The final version may differ from this version. the parent C7G was poorly permeable and not detectable in rat plasma. As expected, in vitro anaerobic incubation of C7G revealed a rapid and complete hydrolysis of C7G
by rat gut microbiota, while the aglycone calycosin generated was highly stable in gut microbiota. Although recent studies reported demethylation and dehydroxylation of C7G in rat gut microbiota (Chen et al., 2011) or human gut bacterial isolates (Zhang et al., 2014) , deglycosylation seems to be the dominant metabolic pathway. In view of the high permeability (~10 -5 cm.s -1 ), calycosin formed is likely to stay shortly in gut lumen, not allowing it be further transformed by gut microbiota or produce other metabolites in significant amounts in vivo.
The aglycone calycosin was only detected in minor amount shortly after oral administration of C7G. Rapid regioselective glucuronidation is the main reason for the low exposure of the aglycone. The resultant 3′-O-glucuronide (G2) appeared as the main circulating form in the plasma and still stayed in the systemic circulation by the end of the experiment (24h). Although previous reports revealed calycosin conjugates as the major form in rats (Chen et al., 2011; Zhang et al., 2012) or zebrafish larvae (Hu et al., 2012) in vivo, they failed to unambiguously assign the 3′-glucuronide as the major circulating form, not even to mention the pro-angiogenic effects of the metabolite. The 3′-O-glucuronide was also found to be the major metabolite in human liver microsomes (Ruan and Yan, 2014) justifying the inter-species correlation.
Although C7G showed a moderate intestinal permeability, it was not detected in gut microbiota from the glycoside as many gut bacterial strains use glucose as one of the main carbon and energy sources (Macfarlane and Macfarlane, 1997) . If so, one can expect that other natural glucosides which can be deglycosylated by gut microbiota to provide sugar source to the later may modulate gut microbiota growth.
Since C7G was depleted by gut microbiota within 2h of incubation while the calycosin generated was relatively stable in gut microbiota ( Figure 2C ), so we speculate that calycosin may also contribute to the probiotics-like effect observed, which warrants further study.
There are a few studies reporting bioactivities of flavonoid conjugates in vivo.
The phase II conjugates, sulfates or glucuronides, have been reported antioxidation (Terao, 1999) , neuroprotective (Ho et al., 2013) , anti-inflammation (Granica et al., 2013) . In addition to a notable immune-enhancing effect, Astragali Radix is also commonly used for treating cardiovascular disorders and has been shown to possess angiogenic effect in previous studies (Tang et al., 2010; Li et al., 2011) . Our previous study has revealed a pro-angiogenic activity of calycosin on HUVECs in vitro and zebrafish in vivo (Tang et al., 2010) which comes from an action on estrogen receptors.
When compared with calycosin, the major in vivo metabolite calycosin 3′-O-glucuronide showed rapid and comparable or more potent effect on promoting angiogenesis in HUVEC cells and zebrafish.
In conclusion, the present study demonstrated that the presystemic interplay between C7G and gut microbiota resulted in not only the metabolite producing pro-angiogenic effects, but also the probiotics-like actions of the parent compound, 
